CAR-T药进入商保创新药目录，五款百万级别产品成大赢家

Core Viewpoint - The inclusion of five CAR-T cell therapies in the first edition of the "Commercial Health Insurance Innovative Drug Directory" marks a significant breakthrough for these high-cost treatments, which have previously struggled to gain access to national insurance negotiations [2][5]. Group 1: CAR-T Cell Therapies Overview - Five CAR-T cell therapies have been successfully included in the directory: Fosun Kite's Acarbose Injection, WuXi AppTec's Regeneron Injection, Huyuan Biotech's Nacarbose Injection, Reindeer Biotech's Ikcarbose Injection, and Kanjin Pharmaceutical's Zewokarbose Injection [2]. - Among these, Huyuan Biotech's Nacarbose Injection is priced at 999,000 yuan per dose, making it the only CAR-T therapy priced below one million yuan, while WuXi AppTec's Regeneron Injection is the most expensive at 1,290,000 yuan per dose [2]. Group 2: Significance of Inclusion - The entry of these CAR-T therapies into the commercial insurance directory is seen as a major milestone in establishing a multi-tiered, institutionalized payment system for high-value innovative drugs in China [5]. - This development is expected to create a sustainable and predictable market access pathway for high-value drugs, including those considered "sky-high priced," providing a reference directory for all commercial health insurance products [5]. Group 3: Cost and Accessibility - Some CAR-T products have already penetrated the commercial insurance market, particularly through local health insurance projects, with reported price reductions of at least 15% for these therapies compared to local health insurance plans [6]. - The production costs of CAR-T therapies are significantly influenced by the use of expensive lentiviral vectors sourced from foreign suppliers, which has historically limited the pricing of these therapies [4]. Group 4: Implementation Challenges - The successful inclusion of CAR-T therapies in the directory raises questions about how to effectively implement and promote these therapies in hospitals, as the directory's impact ultimately depends on hospital adoption [6]. - Recent policies from the National Healthcare Security Administration and the National Health Commission have alleviated concerns among hospitals and physicians regarding cost assessments, which could facilitate the entry of these innovative drugs into hospitals [7][8].